MedTrace Logo

L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer

NCT04203641 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-05-06

No results posted yet for this study

Summary

This study will evaluate the safety and tolerability of escalating doses of L-DOS47 in combination with doxorubicin, as well as preliminary anti-tumor activity in patients with previously treated advanced pancreatic cancer.

Conditions

  • Pancreas Cancer

Interventions

BIOLOGICAL

L-DOS47

A treatment cycle will be 28 days, with patients receiving L-DOS47 on Days 1, 8, 15, and 22.

DRUG

Doxorubicin

A treatment cycle will be 28 days, with patients receiving doxorubicin on Days 2, 9, 16 and 23

Sponsors & Collaborators

  • Theradex

    collaborator INDUSTRY

  • Helix BioPharma Corporation

    lead INDUSTRY

Principal Investigators

  • Erkut Borazanci, MD · Scottsdale Healthcare Hospitals DBA HonorHealth

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-11
Primary Completion
2024-10-24
Completion
2024-10-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04203641 on ClinicalTrials.gov